Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Breaking through a roadblock in prostate cancer research: an update on human model systems.

Toivanen R, Taylor RA, Pook DW, Ellem SJ, Risbridger GP.

J Steroid Biochem Mol Biol. 2012 Sep;131(3-5):122-31. doi: 10.1016/j.jsbmb.2012.01.005. Epub 2012 Feb 8. Review.

PMID:
22342674
2.

YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

Nakahara T, Kita A, Yamanaka K, Mori M, Amino N, Takeuchi M, Tominaga F, Hatakeyama S, Kinoyama I, Matsuhisa A, Kudoh M, Sasamata M.

Cancer Res. 2007 Sep 1;67(17):8014-21. Erratum in: Cancer Res. 2012 Aug 1;72(15):3886. Mori, Masamichi [added]; Amino, Nobuaki [added]; Hatakeyama, Shinji [added];Minematsu, Tsuyoshi [removed]; Shirasuna, Kenna[removed].

3.

Novel therapies for metastatic castrate-resistant prostate cancer.

Dayyani F, Gallick GE, Logothetis CJ, Corn PG.

J Natl Cancer Inst. 2011 Nov 16;103(22):1665-75. doi: 10.1093/jnci/djr362. Epub 2011 Sep 13. Review.

4.

Ex vivo culture of human prostate tissue and drug development.

Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM.

Nat Rev Urol. 2013 Aug;10(8):483-7. doi: 10.1038/nrurol.2013.126. Epub 2013 Jun 11. Review.

PMID:
23752995
5.

Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer.

Attar RM, Jure-Kunkel M, Balog A, Cvijic ME, Dell-John J, Rizzo CA, Schweizer L, Spires TE, Platero JS, Obermeier M, Shan W, Salvati ME, Foster WR, Dinchuk J, Chen SJ, Vite G, Kramer R, Gottardis MM.

Cancer Res. 2009 Aug 15;69(16):6522-30. doi: 10.1158/0008-5472.CAN-09-1111. Epub 2009 Aug 4.

6.

[From tumor tissue via primary cultures to xenograft models: a functional approach in prostate cancer research].

Saar M, Kamradt J, Jung V, Stöckle M, Unteregger G.

Urologe A. 2011 Aug;50(8):961-7. doi: 10.1007/s00120-011-2630-7. German.

PMID:
21728008
7.

The radiation response of hormone-resistant prostate cancer induced by long-term hormone therapy.

Wu CT, Chen WC, Liao SK, Hsu CL, Lee KD, Chen MF.

Endocr Relat Cancer. 2007 Sep;14(3):633-43.

8.

Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion.

Conrad F, Zhu X, Zhang X, Chalkley RJ, Burlingame AL, Marks JD, Liu B.

J Mol Med (Berl). 2009 May;87(5):507-14. doi: 10.1007/s00109-009-0446-3. Epub 2009 Feb 14.

9.

Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer.

Andrzejewski T, Deeb D, Gao X, Danyluk A, Arbab AS, Dulchavsky SA, Gautam SC.

Oncol Res. 2008;17(6):257-67.

PMID:
19192720
10.

Current management of advanced and castration resistant prostate cancer.

Gomella LG, Petrylak DP, Shayegan B.

Can J Urol. 2014 Apr;21(2 Supp 1):1-6.

11.

Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines.

Gu Y, Li H, Miki J, Kim KH, Furusato B, Sesterhenn IA, Chu WS, McLeod DG, Srivastava S, Ewing CM, Isaacs WB, Rhim JS.

Exp Cell Res. 2006 Apr 1;312(6):831-43. Epub 2006 Jan 17.

PMID:
16413016
12.

Modeling prostate cancer in mice: limitations and opportunities.

Hensley PJ, Kyprianou N.

J Androl. 2012 Mar-Apr;33(2):133-44. doi: 10.2164/jandrol.111.013987. Epub 2011 Jun 16. Review.

13.

Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells.

Drees M, Dengler WA, Roth T, Labonte H, Mayo J, Malspeis L, Grever M, Sausville EA, Fiebig HH.

Clin Cancer Res. 1997 Feb;3(2):273-9.

14.

The current state of preclinical prostate cancer animal models.

Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL.

Prostate. 2008 May 1;68(6):629-39. doi: 10.1002/pros.20726.

15.

Treatment options in hormone-refractory prostate cancer: current and future approaches.

Harris KA, Reese DM.

Drugs. 2001;61(15):2177-92. Review.

PMID:
11772129
16.

Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion.

Bansal N, Davis S, Tereshchenko I, Budak-Alpdogan T, Zhong H, Stein MN, Kim IY, Dipaola RS, Bertino JR, Sabaawy HE.

Prostate. 2014 Feb;74(2):187-200. doi: 10.1002/pros.22740. Epub 2013 Oct 24.

17.

Pre-clinical mouse models of human prostate cancer and their utility in drug discovery.

Park SI, Kim SJ, McCauley LK, Gallick GE.

Curr Protoc Pharmacol. 2010 Dec;Chapter 14:Unit 14.15. doi: 10.1002/0471141755.ph1415s51.

18.

Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.

Okegawa T, Nutahara K, Higashihara E.

J Urol. 2008 Oct;180(4):1342-7. doi: 10.1016/j.juro.2008.06.021. Epub 2008 Aug 15.

PMID:
18707699
19.

Evaluating baculovirus as a vector for human prostate cancer gene therapy.

Swift SL, Rivera GC, Dussupt V, Leadley RM, Hudson LC, Ma de Ridder C, Kraaij R, Burns JE, Maitland NJ, Georgopoulos LJ.

PLoS One. 2013 Jun 6;8(6):e65557. doi: 10.1371/journal.pone.0065557. Print 2013.

20.

Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.

Logothetis CJ, Navone NM, Lin SH.

Clin Cancer Res. 2008 Mar 15;14(6):1599-602. doi: 10.1158/1078-0432.CCR-07-4603. Review.

Items per page

Supplemental Content

Write to the Help Desk